Trifecta Capital Advisors LLC Takes $6.02 Million Position in Thermo Fisher Scientific Inc. $TMO

Trifecta Capital Advisors LLC purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 12,002 shares of the medical research company’s stock, valued at approximately $6,017,000.

Several other large investors also recently bought and sold shares of TMO. North Dakota State Investment Board purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at approximately $7,505,000. Boston Trust Walden Corp increased its stake in shares of Thermo Fisher Scientific by 9.7% in the fourth quarter. Boston Trust Walden Corp now owns 43,973 shares of the medical research company’s stock worth $25,480,000 after buying an additional 3,873 shares during the last quarter. Xponance LLC raised its holdings in Thermo Fisher Scientific by 8.1% in the fourth quarter. Xponance LLC now owns 59,295 shares of the medical research company’s stock valued at $34,358,000 after acquiring an additional 4,436 shares in the last quarter. Hudson Value Partners LLC grew its holdings in Thermo Fisher Scientific by 24.9% during the 2nd quarter. Hudson Value Partners LLC now owns 16,653 shares of the medical research company’s stock worth $8,349,000 after acquiring an additional 3,317 shares in the last quarter. Finally, Sandro Wealth Management LLC bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth about $2,089,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

TMO opened at $588.17 on Monday. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The company’s 50-day moving average price is $529.37 and its 200 day moving average price is $508.75. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $643.99. The firm has a market cap of $217.48 billion, a price-to-earnings ratio of 31.64, a price-to-earnings-growth ratio of 2.39 and a beta of 0.84.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. The company had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.Thermo Fisher Scientific’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.11%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on TMO. Robert W. Baird cut their target price on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Wells Fargo & Company lowered their price objective on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Wolfe Research began coverage on Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price objective on the stock. HSBC lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating and decreased their target price for the stock from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Finally, Royal Bank Of Canada boosted their price target on Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a report on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $619.41.

Insider Buying and Selling

In related news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $565.00, for a total value of $226,000.00. Following the sale, the chief operating officer directly owned 24,651 shares in the company, valued at $13,927,815. This trade represents a 1.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 4,608 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $586.12, for a total transaction of $2,700,840.96. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 52,053 shares of company stock valued at $30,643,589 in the last three months. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.